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Abstract
Background: More knowledge about sensitization patterns in early infancy, including 
impact of molecular allergology, is needed to help predict future allergy development 
more accurately.
Objective: We aimed to determine the prevalence and patterns of allergic sensitiza-
tion at 3 months of age, and explore possible associated factors.
Methods: From the Scandinavian antenatally recruited PreventADALL mother– child 
cohort, we included 1110 3- month infants with available serum. Sensitization was 
defined as s- IgE of ≥0.1 kUA/L by Phadiatop Infant
® (ThermoFisher Scientific) includ-
ing birch, cat, grass, dog, milk, egg, peanut and wheat. Further ImmunoCAP analy-
ses to ovomucoid, casein, Ara h 1- 3, omega- 5- gliadin were performed in food extract 
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1  |  INTRODUC TION
The development of allergic sensitization, that is presence of 
allergen- specific immunoglobulin E antibodies (s- IgE), is the basis 
of many hypersensitivity reactions to food and inhalant allergens 
and is often a precursor to later development of atopic dermati-
tis, food allergy, asthma, and allergic rhinitis.1 The development 
is dynamic throughout childhood, and the IgE profile seems 
to affect the course, symptoms and the severity of allergic dis-
eases.2 However, some individuals develop sensitization without 
clinical symptoms of allergy.3 Allergic sensitization can be di-
agnosed by measuring s- IgE in serum or by skin prick test using 
allergen extracts. Established in recent years, methods of molec-
ular allergology enable differentiation between cross- reactive or 
species- specific allergen protein molecules, and allergen protein 
molecules associated with mild or severe allergic reactions.4,5 
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s- IgE- positive children. Maternal sensitization was defined as s- IgE ≥ 0.35 kUA/L 
to Phadiatop® (inhalant allergen mix) and/or Fx5 (food allergen mix) at 18- week 
pregnancy.
Results: Overall 79 (7.3%) infants had specific sensitization, many with low s- IgE- levels 
(IQR 0.16– 0.81 kUA/L), with 78 being sensitized to food extract allergens; 41 to egg, 
27 to milk, 10 to peanut, and 25 to wheat. A total of 62/78 were further analysed, 18 
(29%) had s- IgE to ovomucoid, casein, Ara h 1- 3 and/or omega- 5- gliadin. Eight infants 
(0.7%) were sensitized to inhalant allergens. Maternal sensitization to food allergens 
was associated with infant sensitization, odds ratio 3.64 (95% CI 1.53– 8.68).
Conclusion: Already at 3 months of age, 7% were sensitized to food, mostly without 
detectable s- IgE to food allergen molecules, and <1% to inhalant allergens. Maternal 
food sensitization was associated with infants’ sensitization.
K E Y W O R D S
birth cohort, IgE, immunoglobulin E antibodies, molecular allergology, sensitization
G R A P H I C A L  A B S T R A C T
At 3 months of age, 7% of the infants are sensitized to food, and few of them have detectable s- IgE to food allergen molecules. Very few 
infants, <1%, are sensitized to inhalant allergens. Maternal food sensitization is associated with infants’ sensitization, odds ratio 3.64 (95% CI 
1.53– 8.68).
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With the analyses of the allergen protein molecules casein for 
cow's milk protein,6 ovomucoid for egg,7 Ara h 1, Ara h 2, Ara h 3 
for peanut,8 and omega- 5- gliadin for wheat,9 it is now possible to 
give a more clinically appropriate diagnosis of specific food allergy, 
when oral food challenge is not feasible.
The exact time point when the child's IgE antibody produc-
tion starts to develop and can be measured is not clear. Although 
IgE in cord blood has been found to be identical with maternal 
IgE, the relationship with the child's own IgE production quickly 
disappears.10- 12 During the first year of life sensitization devel-
ops rapidly. Previous studies have reported that the prevalence 
rates for any sensitization at 3 months of age vary between 5% 
and 13%,13- 16 and at 12– 18 months, the prevalence of sensitiza-
tion to at least one allergen ranges between 16% and 21%.17,18 
To our knowledge, documentation of allergic sensitization data 
in 3- month- old infants in relation to that of their mothers during 
pregnancy is sparse. Especially, there is a knowledge gap concern-
ing the development of IgE against specific allergen molecules in 
young children.
The most commonly reported risk factors for the development 
of sensitization in children older than 1 year include parental atopic 
history, male gender and atopic dermatitis.13,19- 23 However, it is not 
clear to what extent allergic sensitization or other atopic traits in 
the mother impact the development of sensitization in her infant. 
Furthermore, due to the lack of studies assessing IgE in a large pop-
ulation of young infants, there is a need to identify risk for sensitiza-
tion and the impact of perinatal and infant factors, including mode 
of delivery, birth weight, gender and maternal factors such as BMI, 
smoking, and socio- economic factors.
Birth cohorts are ideal to study the development of atopic 
disease in children, and antenatal recruitment including data of 
maternal sensitization and other potential risk factors enables 
identification of the most prominent risk factors at the start of 
life.
2  |  AIM
Our aim was to determine patterns of allergic sensitization at 
3 months of age, and explore whether maternal and perinatal 
associated risk factors are associated with sensitization in early 
infancy.
3  |  METHODS
3.1  |  Study design, setting and population
PreventADALL (Preventing Atopic Dermatitis and ALLergies in 
Children) is a Nordic population- based mother– child birth cohort 
where the infants at birth were included in a randomized clini-
cal trial of two interventions (food and skin). Briefly, 2697 preg-
nant women were recruited at the 18- week routine ultrasound 
examination from December 2014 until October 2016, in Norway 
(Oslo and Østfold) and Sweden (Stockholm) as described else-
where.24 Inclusion criteria for enrolment in pregnancy were suffi-
cient maternal language skills, singleton or twin pregnancy without 
severe malformations or disease. Enrolment at gestational week 18 
included a brief structured interview, and measurements of height, 
weight and blood pressure measures as well as blood sampling. The 
included women completed detailed electronic questionnaires both 
at enrolment and at 34 weeks of pregnancy including information 
on socio- demographics, atopic heredity, living conditions, smoking 
and maternal antenatal health.
Their offspring (N = 2396) were included at birth and randomized 
to four different groups (skin intervention from 2 weeks of age, early 
food introduction from 3 months of age, both skin intervention and 
early food introduction, or controls), given a gestational age of ≥35 
and no severe disease. Birth data were collected from birth charts 
at inclusion of the newborn as described elsewhere.24 The visit at 
3 months of age included anthropometric measurements, clinical 
examination as well as blood sampling for IgE measures from the 
participating 1110 infants.
The present study included all 1110 infants who at 3 months of 
age had available serum for IgE analyses (Figure 1) and their mothers.
3.2  |  Sensitization measurements
Blood samples from the pregnant women were collected at in-
clusion around 18 weeks gestational age, set for one hour, spun 
for serum extraction, aliquoted and stored at −80°C until ana-
lysed for allergen- specific IgE levels using ImmunoCAP (Thermo 
Fischer Scientific): from the Phadiatop® (birch, cat, dog, horse, 
grass, mugwort, house dust mites (Dermatophagoides pteronyssi-
nus), and Cladosporium herbarum) and Fx5 (cow's milk, egg white, 
wheat, peanut, cod). If a sample scored positive IgE ≥ 0.35 kUA/L 
to one of the mixes, further analyses of specific IgE towards aller-
gens included in the mixes were performed. Allergic sensitization 
in women was defined as IgE levels ≥0.35 kUA/L. In this study, 
results from specific IgE against cod, horse or Cladosporium herba-
rum were not used.
Blood samples were collected from the infants at the 
3 months visit, set for one hour, spun for serum extraction, ali-
quoted and stored at −80°C until analysis of specific (s- ) IgE to 
food and inhalant allergens first by using ImmunoCAP Phadiatop 
Infant® (birch, cat, dog, grass, cow's milk, egg white, peanut). 
In case of positive Phadiatop Infant (≥0.1 kUA/L), s- IgE to each 
allergen in the mix was further analysed. Additionally, s- IgE to 
wheat extract was analysed in all infants with available sera. In 
infants that scored positive to whole extract (IgE ≥ 0.1 kUA/L), 
we further analysed relevant allergen components within the 
food allergens; for egg ovomucoid (Gal d 1), for milk casein, for 
peanut Ara h 1, Ara h 2 and Ara h 3, and for wheat omega- 5- 
gliadin. Infant sensitization was defined as an allergen- specific 
IgE level of ≥0.1 kUA/L.
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3.3  |  Definition of maternal and 
perinatal exposures
Maternal history of atopic dermatitis, allergic rhinitis, asthma and food 
allergy at the time of study inclusion (18 weeks) was defined as self- 
reported doctor confirmed diagnosis of each relevant disease.
Previous deliveries were defined as at least one previous delivery 
at inclusion.
Low maternal age was defined as age below 25 years at inclusion.
Maternal BMI was defined as mother's weight in kilograms divided 
by mother's length in squared metres (kg/m2), measured at time of 
inclusion.
Maternal smoking was defined as answer ‘yes’ to the questions 
‘have you ever smoked’ and ‘do you smoke currently’ specified as 
‘smoked during pregnancy’, ‘smoked but quit recently’ or ‘smoked 
but quit whilst trying to get pregnant’ at time of study inclusion.
Furry pet at home was defined by the answer ‘yes’ to the question 
concerning having a pet at study inclusion time.
Low maternal education level was defined as preliminary school 
only (9/10 years) or less education years.
Low family income was defined as below 300,000 Norwegian/
Swedish crowns (kroner/kronor)/year.
Study country was defined as participant enrolled in Sweden or 
Norway, respectively.
Delivery mode was defined as caesarean section or vaginal delivery.
Low birthweight was defined as a birth weight below 2500 g.
Low gestational age at birth was defined as birth between 35 and 
37 weeks of gestational age.
3.4  |  Statistical analyses
Prevalence rates are expressed as numbers and proportions (as a 
percentage). The chi- squared test was used for comparison of di-
chotomous variables between groups. The Fisher exact test was used 
if one comparison group consisted of 5 observations or less. Group 
IgE levels were expressed as median values and interquartile ranges. 
Two- tailed t test was used on log transformed values for group com-
parisons of IgE levels. p < 0.05 were considered significant. Odds ra-
tios (OR) with 95% confidence intervals (CIs) were calculated using 
logistic regression for the association of sensitization in relation to 
background factors. In the first step, univariate (crude) analyses were 
made for each available maternal or perinatal factor known from the 
literature or clinical knowledge to be of potential importance for al-
lergy development. All estimates with a p- value of 0.2 or below were 
then in a second multivariate analysis included in the adjusted model 
(infant gender, pet at home, low birth weight, maternal sensitization, ma-
ternal food sensitization). Statistical analyses were conducted using 
STATA Statistical Software (16.0).
3.5  |  Ethics
Ethical approval for the PreventADALL study was obtained by the 
regional ethics committee in Stockholm, Sweden, (nr: 2014/2242- 
31/4) and the Regional Committee for Medical and Health Research 
Ethics in South- Eastern Norway (2014/518), and signed informed 
consent were collected from the women and from both parents 
F I G U R E  1  Flow chart of the selection of the study cohort with details of available child blood samples and subsequent analysis of specific 
allergen extract and specific allergen molecules, with cut- off ≥0.1 kUA/L)
Specific allergen molecule
positive
Specific allergen extract positive
Allergy Diagnostics
3 months children providing






Phadiatop infant mix *
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of the infants. PreventADALL is registered in ClinicalTrials.gov, 
Identifier: NCT02449850.
4  |  RESULTS
A flow chart of the entire cohort is presented in online repository 
Figure S2. In general, the participating expectant mothers were well 
educated, lived with a partner and were mainly of urban population, 
as previously reported by Carlsen et al.24 The background character-
istics for the 1100 infants with available serum were not significantly 
different from those who did not have available serum (n = 1286) 
and who were therefore not included in the present study (Table 1).
Analysis of Phadiatop infant was available for all 1110 infants, 
s- IgE to wheat in 1092 and s- IgE to the specific allergens within 
the Phadiatop Infant in 1086 infants as shown in Figure 1. Overall, 
87/1110 infants had a positive Phadiatop infant mix (including birch, 
cat, dog, grass, cow's milk, egg white and peanut allergens), while 25 
of the 1092 had s- IgE to wheat IgE.
As presented in Table S1, 7.3% (n = 79) of 1086 infants with suf-
ficient amount of sera for allergen- specific IgE- analysis were sensi-
tized to at least one specific allergen, with median s- IgE levels among 
all positive s- IgE values of 0.23 kUA/L (IQR 0.16– 0.81 kUA/L). All, but 
one of these infants (78/79) were sensitized to a food allergen, most 
commonly to egg (3.7%), but also to cow's milk (2.5%), wheat (2.3%) 
and peanut (0.9%), Figure 2.
Among the 78 food- sensitized infants, 62 children's sera were 
available for further analysis: only 18/62 (29%) were identified with 
s- IgE to a food allergen molecule. In the 41 infants with s- IgE to egg, 
8/33 (24%) with sufficient serum for further analyses were sen-
sitized to ovomucoid, Figure 2. In infants with s- IgE towards milk 
10/24 (42%) were sensitized to casein, and in infants with s- IgE to 
wheat 6/18 (33%) were sensitized to omega- 5- gliadin. Among the 
infants with s- IgE towards peanut, 3/7 (43%) were sensitized to Ara 
h2. No infants presented with sensitization towards Ara h1 or Ara 
h3.
In five of the eight infants who were sensitized to ovomucoid, s- 
IgE to egg white was 1.0 kUA/L or above. Similar patterns with higher 
food extract IgE levels in allergen molecule sensitized infants was 
seen for milk, wheat and peanut, but with few observations, not per-
mitting statistical analyses.
Less than one percent of infants were sensitized to inhalant aller-
gens, most commonly towards dogs, observed in seven infants (0.7%) 
and to birch in four infants (0.4%). One infant was exclusively sensi-
tized to inhalant allergen, namely to dog. While 59 of the sensitized 
infants (75%) were sensitized to one allergen only (mono- sensitized), 
20 (25%) were polysensitized with 12 infants (14%) sensitized to two 
and 8 infants (10%) sensitized to three or more allergens, respec-
tively, online repository (Figure S1).
Maternal allergic sensitization as well as other general back-
ground characteristics and reported allergic diseases are presented 
for the mother– child cohort as well as for all women enrolled in 
the PreventADALL study for comparison in online repository text, 
Tables S2 and S3 and Figures S2– S6.
The sensitization pattern within mother– child pairs differed 
significantly, with infants dominantly sensitized to food allergens 
while the pregnant women were mostly sensitized to inhalant aller-
gens, Figure 3. Infants who were sensitized had more often mothers 
TA B L E  1  General characteristics of study cohort infants, N = 1110 versus no blood sample cohort N = 1286 and entire cohort N = 2396
Study cohort (N = 1110) No blood sample (N = 1286) Original cohort (N = 2396)
n % (95% CI) n % (95% CI) n % (95% CI)
Study country (N = 1110/2396)
Norway 806 72.6 (69.9– 75.2) 1073 83.4 (81.3– 85.4) 1879 78.4 (76.7– 80.0)
Sweden 304 27.4 (24.7– 30.1) 213 16.5 (14.6– 18.7) 517 21.6 (19.9– 21.3)
Male sex (N = 1110/2396) 615 55.5 (52.5– 58.4) 642 49.9 (47.1– 52.7) 1258 52.5 (50.5– 54.5)
Delivery mode (N = 1110/2396)
Vaginal delivery 925 83.8 (81.0– 85.4) 1074 83.5 (81.4– 85.5) 1999 83.4 (81.9– 84.9)
Caesarean section 185 16.7 (14.5– 19.0) 212 16.5 (14.5– 18.6) 397 16.6 (15.1– 18.1)
Birth weight (N = 1104/2386)
Low <2500 g 16 1.4 (0.8– 2.3) 23 1.8 (1.1– 2.7) 39 1.6 (1.2– 2.2)
2500– 4499 g 1058 95.8 (94.5– 96.9) 1223 95.4 (94.1– 96.5) 2281 95.6 (94.6– 96.4)
>4500 g 30 2.7 (1.8– 3.8) 36 2.8 (1.9– 3.9) 66 2.8 (2.1– 3.5)
Gestational age (N = 1092/2347)
Low <37 weeks 132 12.1 (10.2– 14.2) 141 11.6 (10.4– 13.0) 273 11.6 (10.4– 13.0)
37– 41 weeks 938 85.9 (83.7– 87.9) 1088 86.7 (84.7– 88.5) 2026 86.3 (84.8– 87.7)
42 weeks 22 2.0 (1.3– 3.0) 26 2.1 (1.3– 3.0) 48 2.1 (1.5– 2.7)
Days old (IQR) Days old (IQR) Days old (IQR)
Median age at 3 m visit, days (IQR) 93.0 (IQR 87– 97) 92.5 (IQR 88– 97) 92.8 (IQR 88– 97)
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with food sensitization (12%) than did non- sensitized infants (3.5%) 
(p < 0.001), while maternal sensitization to inhalant allergens was 
similar among sensitized (43%) and non- sensitized infants (37%) 
(p > 0.2). Among the sensitized infants, seven had mothers who were 
sensitized to peanut, of whom four reported a peanut allergy, while 
none of these infants were sensitized to peanut.
Sensitization at 3 months of age was significantly associated only 
with maternal food sensitization in logistic regression, remaining sig-
nificant after adjusting for the other covariates (adj OR 3.64, 95% 
CI 1.53– 8.68) (Table 2). None of the other maternal and perinatal 
factors were significantly associated with infant sensitization. No 
correlation was found between the number of sensitizing allergens 
in the mothers and sensitization in the infants. As the skin interven-
tion was implemented from 2 weeks of age, we stratified allergic 
sensitization by skin intervention, observing similar sensitization 
among infants in the skin intervention group (6.7%) and the non- skin 
intervention group (7.7%) (p = 0.557).
5  |  DISCUSSION
5.1  |  Main findings
This is to our knowledge the first time a large international 
population- based mother– child cohort has provided specific IgE 
as well as allergen molecule data from young infants. Seven per 
cent of infants at 3 months of age had sensitization towards foods, 
most commonly to egg, while sensitization to inhalant allergens 
was observed in less than one percent. In contrast, their mothers 
had mostly IgE towards inhalant allergens during mid- pregnancy. 
Further, few infants expressed IgE to food allergen molecules at this 
age. Maternal food sensitization was found to be a significant risk 
factor for infant sensitization.
Our finding that infants express s- IgE already at 3 months of age, 
although at low levels, is in line with earlier studies,14,21 Previous 
studies, such as the BEAT study,25 measured sensitization by skin 
prick test, not enabling direct comparison of levels between the stud-
ies. The infants in our study were mostly sensitized to food allergens, 
with <1% being sensitized to inhalant allergens. The prevalence of 
any sensitization in our study was lower than earlier described by 
the Danish population- based DARC study of 562 children13 who 
reported 12.5% prevalence of any sensitization, but slightly higher 
than the nine centre Norwegian Bronchiolitis study who studied 368 
bronchiolitis patients and 224 healthy controls and found that 5.5% 
had allergen- specific IgE antibodies at age 0– 3 months.16
Our rates of s- IgE towards milk (2.5%) and egg (3.7%) where 
higher than in the DARC study that found s- IgE towards milk in 1.7% 
and towards egg in 2.5% of the infants at 3 months of age,13 and 
more in line with the Australian BEAT study who followed 319 in-
fants at risk for allergy, where 3.9% were sensitized to egg measured 
by skin prick test at 4 months of age.25
The prevalence of a reported doctor diagnosis of asthma, atopic 
dermatitis and food allergy among pregnant women was higher in 
our cohort compared to other population- based studies, possibly 
due to a slight bias towards allergic women being more likely to par-
ticipate in a study aiming at primary prevention of allergic diseases. 
F I G U R E  2  Specific IgE sensitization (≥0.1 kUA/L) prevalence in children 3 months of age (%) N = 79 and co- existing allergen 
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Additionally, differences between countries or slightly different 
definitions for the specific diagnoses could also explain variation 
between studies, even though most comparable studies used sim-
ilar self- reported questionnaires.26,27 However, for allergic rhinitis 
the reported prevalence was lower in our study (20%) as compared 
to the Japanese JECS study that reported 36% of 99,103 pregnant 
women to suffer from allergic rhinitis.27 The women mainly pre-
sented IgE towards inhalant allergens, and the prevalence in the 
present study of any sensitization of 37.2% was almost identical to 
what Melén et al28 found in 24- year- old women in the Swedish birth 
cohort BAMSE (n = 1244), possibly due to the fact that both cohorts 
included Scandinavian populations only. This correlates quite well to 
the 35% sensitization prevalence by SPT found by in an adult swed-
ish cohort.29 We found s- IgE towards peanut to be the most com-
mon food allergen (in 2.6%), in contrast the s- IgE rate towards egg 
was only 0.6%, which is lower than a previous study that presented 
data on s- IgE towards food allergen, reporting a sensitization preva-
lence towards egg in 1%.27
We identified maternal food sensitization as a risk factor for 
early infant sensitization, with a three- fold increased risk. Similar 
findings were reported in the PASTURE birth cohort, were infants 
from five different European countries were followed between birth 
and 12 months of age.23 Other risk factors for early sensitization 
reported by others, such as male gender,14 could not be confirmed 
in our study.
Several previous studies have investigated the correlation be-
tween maternal IgE during pregnancy, cord blood IgE and early 
sensitization in the infant, with conflicting results regarding an as-
sociation with maternal sensitization.10- 12,30- 32 In the present study, 
we have not used cord blood IgE. Previous findings mainly found 
IgE cord blood profiles originating from the mother, indicating no 
own production of allergen s- IgE from the child at birth. Bonnelykke 
et al reported no relation between maternal IgE profile and infant IgE 
at 6 months.33 After evaluating our IgE data from the mothers and 
the infants at 3 months with clearly different IgE patterns, the s- IgE 
detected at 3 months of age represents infants’ own IgE production.
5.2  |  Strengths and limitations
Among the strengths of the present study is the population- 
based design and the relatively large size of the study population. 
Additionally, it is a multi- centre study and comprises a vast num-
ber of prospectively collected data, including extensive antenatally 
F I G U R E  3  Specific IgE sensitization prevalence among pregnant women (≥0.35 kUA/L) and children (≥0.1 kUA/L) at 3 months of age, 
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recorded baseline data regarding maternal atopic history. It also 
encompasses sensitization data from both mothers and infants, and 
especially on the molecular allergen level that is unique in such small 
infants.
One of the limitations is the cut- off level ≥0.35 kUA/L of the 
Phadiatop and Fx5 allergen mixes used for analysing sensitization in 
the pregnant women. The samples were not analysed for individual 
allergens if the mixes did not pass this level. However, the cut- off 
≥0.35 is in the one currently used in clinical setting for Phadiatop. 
Since most previous research has used a cut- off ≥0.35 kUA/L, it also 
allows us to compare our results with other studies.
Blood sampling at 3 months of age in a general infant cohort is 
challenging, with an insufficient amount of serum in 16.4% rendering 
some IgE analyses incomplete. As a consequence, we cannot rule out 
a slight underreporting of allergic sensitization in our study, although 
we did prioritize food allergens for analyses. IgE for wheat was ana-
lysed separately in the infants since wheat extract was not included 
in the original Phadiatop Infant mix. Thus, all included infants were 
analysed for wheat, not only those positive in the Infant mix, which 
was the procedure for all other analysed allergens. This might have 
resulted in the numbers of positive IgE to wheat cases to be slightly 
overrepresented.
In addition to being an observational study, The PreventADALL 
study is a randomized clinical trial with the skin intervention starting 
at 2 weeks of age, thus preceding blood sampling at 3 months of age. 
We therefore stratified analyses by skin intervention, but found no 
significant differences among infants in the skin intervention group 
and the non- interventional group. While some individuals theoreti-
cally could have started food introduction before age 3 months, out-
side the study protocol, we have no reason to assume this would be 
different depending on intervention group.
Our results of maternal sensitization of 38.2% correlates well 
to other similar cohorts,28- 29 and this together with the large study 
sample and settings of the PreventADALL indiqates that the gener-
alizability is adequate and the results reproducible in other cohorts 
with similar settings.
5.3  |  Clinical implication and future research
At 3 months of age, less than 30% of food extract sensitized infants 
express s- IgE antibodies to clinically relevant allergen molecules with 
a possible implication of tolerance development to these foods. Our 
finding of an association between infant sensitization and maternal 
TA B L E  2  Maternal and perinatal factors associated with any infant sensitization at 3 months of age (inhalant or food specific 
IgE ≥ 0.1 kUA/L) N = 79
n/N (%) Crude OR (95% CI)
Adjusteda  OR (95% 
CI)
Offspring gender (ref female) 492/1104 (44.6) 0.60 (0.41– 1.07) 0.68 (0.40– 1.13)
Maternal sensitization (any, ≥0.35 kUA/L) 399/1065 (37.4) 1.42 (0.88– 2.28) 1.13 (0.66– 1.94)
Maternal food sensitization (any, 
≥0.35 kUA/L)
44/1068 (4.1) 3.67 (1.69– 7.96) 3.64 (1.53– 8.68)
Maternal inhalant sensitization (any, 
≥0.35 kUA/L)
404/1068 (37.8) 1.28 (0.80– 2.06)
Study country (ref Norway) 802/1104 (72.6) 1.04 (0.62– 1.75)
Low education 101/999 (10.1) 1.12 (0.52– 2.41)
Low income 7/1104 (0.6) 0.66 (0.31– 1.40)
Maternal tobacco use 274/1005 (27.3) 1.43 (0.85– 2.43)
Maternal BMI >25 423/1090 (38.8) 0.89 (0.55– 1.44)
Maternal BMI >30 95/1090 (8.7) 0.88 (0.37– 2.07)
Pets at home 230/1005 (22.9) 0.30 (0.35– 1.11) 0.50 (0.24– 1.03)
Maternal allergy (any) 632/1005 (62.9) 1.35 (0.84– 2.17)
Maternal asthma, rDD 164/1005 (16.3) 1.24 (0.67– 2.27)
Maternal food allergy, rDD 128/1005 (12.7) 1.38 (0.72– 2.64)
Maternal atopic dermatitis, rDD 183/1005 (18.2) 1.40 (0.79– 2.47)
Maternal allergic rhinitis, rDD 212/1005 (21.1) 0.88 (0.48– 1.61)
Caesarean section (ref PN) 185/1104 (16.7) 1.28 (0.72– 2.28)
Previous deliveries (ref 0) 410/555 (73.9) 1.25 (0.58– 2.68)
Low gestational age (<37 weeks) 131/1086 (12.1) 0.69 (0.31– 1.54)
Low birth weight (<2500 g) 16/1098 (1.4) 3.05 (0.85– 10.95) 3.59 (0.70– 18.38)
Abbreviations: PN, vaginal delivery; rDD, self- reported doctor diagnose.
aAdjusted for variables with association p- values of 0.2 or less in the univariate analyses: infant gender, pet at home, low birth weight, maternal 
sensitization, maternal food sensitization.
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food sensitization might indicate that an early intervention could be 
even more beneficial in infants born to mothers with food allergy. 
Further studies are needed, especially regarding the influence of 
early food introduction and the length of the ‘window of oppor-
tunity’. Early introduction of allergenic foods has been associated 
with a lower risk of developing food allergy in subsets of infants at 
high risk34 or in observational studies,35 while a randomized trial in 
a general population- based study failed to replicate the reduced risk 
of food allergy.15 Consequently, some advice against delaying com-
plementary food introduction, in order to initiate oral tolerance.36,37 
The general population- based PreventADALL study will be further 
explored for the possible impact of early complementary food in-
troduction to reduce food allergy in sensitized and non- sensitized 
infants.
6  |  CONCLUSION
At 3 months of age, seven per cent of infants from a general population 
were sensitized to food allergens and less than one percent to inhal-
ant allergens, while s- IgE to food allergen molecules was observed in 
around one of three infants sensitized to food allergens. In contrast, 
sensitization to inhalant allergens was most common among their 
mothers in mid- pregnancy. Maternal food sensitization was found to 
be a significant risk factor for 3 months sensitization among the infants.
ACKNOWLEDG EMENTS
We wish to thank all study participants, the health personnel con-
tributing in recruiting, foetal ultrasound measurements and bio-
logical sampling. We also like to thank all the individuals involved 
in facilitating and running the study: Patji Haakon Alnæs- Katjavivi, 
Lene Frost Andersen, Line Arntzen, Hasan Arshad, Petri Auvinen, 
Karina Barhaag, Teresa Løvold Berents, Ann Berglind, Abelone 
Bidstrup, Randi Brøseth, Monica Hauger Carlsen, Oda C. Lødrup 
Carlsen, Kristine Wedum Davanger, Vibeke Dyrseth, Kim Magnus 
Advocaat Endre, Ingvild Essén, Thea Aspelund Fatnes, Pål Fugelli, 
Peter Gaustad, Peder Annæus Granlund, Berit Granum, Malén 
Gudbrandsgard, Sandra Götberg, Tari Haahtela, Susanne Halken, 
Katarina Hilde, Henrik Holmstrøm, Ann Edløy Holstvoll, Geir Håland, 
Maria Ingemansson, Ragnhild Kinge, Mari Kjendsli, Linn Landrø, Jon 
Lunde, Benjamin J Marsland, Nora Nilsson, Monika Nordenbrand, 
Unni C. Nygaard, Céline Pattaroni, Alexis Rapin, Carina Madelen 
Saunders, Kajsa Sedergren, Natasha Sedergren, Katrine Sjøborg, 
Sigrun Irene Skei, Ingebjørg Skrindo, Sigrid Sjelmo, Liv Julie Sørdal, 
Ellen Tegnerud, Lovisa Tolander, Magdalena R. Værnesbranden, Ann 
Kristin M. von Übisch, Johanna Wiik, Angelica Johansen Winger.
CONFLIC T OF INTERE S T
M.P Borres is an employee of Thermo Fisher Scientific. M van Hage 
has received lecture fees from Thermo Fisher Scientific outside the 
submitted work. None of the other authors have any conflict of in-
terest to declare.
AUTHOR CONTRIBUTIONS
Sandra Tedner and Anna Asarnoj participated in design of the study, 
data analysis, and manuscript writing and contributed to data col-
lection. Karen Eline Stensby Bains, Martin Färdig, Sabina Wärnberg 
Gerdin, Hrefna Katrín Gudmundsdóttir, Ina Kreyberg, Live Solveig 
Nordhagen and Eva Maria Rehbinder contributed to data collec-
tion, critically reviewed data and revised the manuscript. Magnus 
P. Borres and Karin C. Lødrup Carlsen participated in design of 
the study, critically reviewed data and revised the manuscript. 
Kai- Håkon Carlsen participated in developing and running of the 
PreventADALL study, critically reviewed data and revised the manu-
script. Guttorm Haugen contributed to running the study, critically 
reviewed data analysis and revised the manuscript. Karin CL Carlsen 
and Gunilla Hedlin participated in initiating, developing the concept, 
design and establishment of the study, critically reviewed data and 
revised the manuscript. Jon Konradsen contributed to the concep-
tion, planning, critically reviewed data and revised the manuscript. 
Christine Monceyron Jonassen participated in developing the con-
cept, design and establishment of the PreventADALL study, critically 
reviewed data analysis and revised the manuscript. Caroline- Aleksi 
Olsson Mägi contributed to data collection, management of the 
study in Stockholm, Sweden, and critically reviewed data and revised 
the manuscript. Björn Nordlund contributed to the conception, plan-
ning and running of the study, critically reviewed data and revised 
the manuscript. Knut Rudi and Annetine Staff participated in devel-
oping the concept, design and establishment of the PreventADALL 
study, critically reviewed data and revised the manuscript. Håvard 
O. Skjerven contributed to the conception, planning and running of 
the study, critically reviewed data and revised the manuscript. Cilla 
Söderhäll participated in developing the concept, design genetic 
and epigenetic sampling and analysis procedures in the study, criti-
cally reviewed data and revised the manuscript. Marianne van Hage 
contributed to the conception, planning of the analyses, critically 
reviewed data and revised the manuscript. Riyas Vettukattil contrib-
uted to managing the database, critically reviewed data and revised 
the manuscript. Björn Nordlund participated in initiating, developing 
the concept, design, establishment and running of the study, criti-
cally reviewed data and revised the manuscript. All authors have ap-
proved the last version before submission.
ORCID
Sandra G. Tedner  https://orcid.org/0000-0003-0157-5407 
Cilla Söderhäll  https://orcid.org/0000-0002-8397-3080 
Karin C. L. Carlsen  https://orcid.org/0000-0002-9257-1198 
Caroline- Aleksi O. Mägi  https://orcid.org/0000-0002-5604-9132 
Håvard O. Skjerven  https://orcid.org/0000-0003-0168-2616 
Marianne van Hage  https://orcid.org/0000-0003-3091-1596 
R E FE R E N C E S
 1. van den Oord RA, Sheikh A. Filaggrin gene defects and risk of de-
veloping allergic sensitisation and allergic disorders: systematic re-
view and meta- analysis. BMJ 2009;339:b2433.
10  |    TEDNER ET al.
 2. Wickman M, Lupinek C, Andersson N, et al. Detection of IgE reac-
tivity to a handful of allergen molecules in early childhood predicts 
respiratory allergy in adolescence. EBioMedicine. 2017;26:91- 99.
 3. Asarnoj A, Hamsten C, Lupinek C, et al. Prediction of peanut allergy 
in adolescence by early childhood storage protein- specific IgE sig-
natures: the BAMSE population- based birth cohort. J Allergy Clin 
Immunol. 2017;140(2):587- 590 e587.
 4. Asarnoj A, Nilsson C, Lidholm J, et al. Peanut component Ara 
h 8 sensitization and tolerance to peanut. J Allergy Clin Immunol. 
2012;130(2):468- 472.
 5. Matricardi PM, Kleine- Tebbe J, Hoffmann HJ, et al. EAACI molecu-
lar allergology user's guide. Pediatr Allergy Immunol. 2016;27(Suppl 
23):1- 250.
 6. Bartuzi Z, Cocco RR, Muraro A, Nowak- Wegrzyn A. Contribution of 
molecular allergen analysis in diagnosis of milk allergy. Curr Allergy 
Asthma Rep. 2017;17(7):46.
 7. Chokshi NY, Sicherer SH. Molecular diagnosis of egg allergy: an up-
date. Expert Rev Mol Diagn. 2015;15(7):895- 906.
 8. Lange L, Beyer K, Kleine- Tebbe J. Benefits and limitations of mo-
lecular diagnostics in peanut allergy: part 14 of the series molecular 
allergology. Allergo J Int. 2014;23(5):158- 163.
 9. Nilsson N, Sjolander S, Baar A, et al. Wheat allergy in children eval-
uated with challenge and IgE antibodies to wheat components. 
Pediatr Allergy Immunol. 2015;26(2):119- 125.
 10. De Amici M, Perotti F, Marseglia GL, et al. Cord and blood levels 
of newborn IgE: Correlation, role and influence of maternal IgE. 
Immunobiology 2017;222(2):450- 453.
 11. Lilja G, Johansson SG, Kusoffsky E, Oman H. IgE levels in cord 
blood and at 4– 5 days of age: relation to clinical symptoms of atopic 
disease up to 18 months of age. Allergy 1990;45(6):436- 444.
 12. Nissen SP, Kjaer HF, Host A, Nielsen J, Halken S. Can family history 
and cord blood IgE predict sensitization and allergic diseases up to 
adulthood? Pediatr Allergy Immunol. 2015;26(1):42- 48. https://doi.
org/10.1111/pai.12264. Epub 12014 Nov 12225.
 13. Kjaer HF, Eller E, Andersen KE, Host A, Bindslev- Jensen C. The 
association between early sensitization patterns and subsequent 
allergic disease. The DARC birth cohort study. Pediatr Allergy 
Immunol. 2009;20(8):726- 734.
 14. Oldak E, Kurzatkowska B, Stasiak- Barmuta A. Natural course of 
sensitization in children: follow- up study from birth to 6 years 
of age, I. Evaluation of total serum IgE and specific IgE antibod-
ies with regard to atopic family history. Rocz Akad Med Bialymst. 
2000;45:87- 95.
 15. Perkin MR, Logan K, Tseng A, et al. Randomized trial of intro-
duction of allergenic foods in breast- fed infants. N Engl J Med. 
2016;374(18):1733- 1743.
 16. Skjerven HO, Hunderi JOG, Carlsen KH, et al. Allergic sensitisation 
in infants younger than one year of age. Pediatr Allergy Immunol. 
2020;31(2):203- 206.
 17. Illi S, von Mutius E, Lau S, et al. The pattern of atopic sensitization is 
associated with the development of asthma in childhood. J Allergy 
Clin Immunol. 2001;108(5):709- 714.
 18. Schoos AM, Chawes BL, Rasmussen MA, Bloch J, Bonnelykke K, 
Bisgaard H. Atopic endotype in childhood. J Allergy Clin Immunol. 
2016;137(3):844- 851 e844.
 19. de Benedictis FM, Franceschini F, Hill D, et al. The allergic sensitiza-
tion in infants with atopic eczema from different countries. Allergy 
2009;64(2):295- 303.
 20. Gabet S, Just J, Couderc R, Seta N, Momas I. Allergic sensitisation in 
early childhood: patterns and related factors in PARIS birth cohort. 
Int J Hyg Environ Health. 2016;219(8):792- 800.
 21. Hattevig G, Kjellman B, Johansson SG, Bjorksten B. Clinical symp-
toms and IgE responses to common food proteins in atopic and 
healthy children. Clin Allergy. 1984;14(6):551- 559.
 22. Simpson A, Tan VY, Winn J, et al. Beyond atopy: multiple patterns 
of sensitization in relation to asthma in a birth cohort study. Am J 
Respir Crit Care Med. 2010;181(11):1200- 1206.
 23. Depner M, Ege MJ, Genuneit J, et al. Atopic sensitization in the first 
year of life. J Allergy Clin Immunol. 2013;131(3):781- 788.
 24. Lodrup Carlsen KC, Rehbinder EM, Skjerven HO, et al. Preventing 
atopic dermatitis and ALLergies in children- the PreventADALL 
study. Allergy 2018;73(10):2063- 2070.
 25. Wei- Liang Tan J, Valerio C, Barnes EH, et al. A randomized trial of 
egg introduction from 4 months of age in infants at risk for egg 
allergy. J Allergy Clin Immunol. 2017;139(5):1621- 1628 e1628.
 26. Lakwijk N, Van Strien RT, Doekes G, Brunekreef B, Gerritsen J. 
Validation of a screening questionnaire for atopy with serum IgE 
tests in a population of pregnant Dutch women. Clin Exp Allergy. 
1998;28(4):454- 458.
 27. Yamamoto- Hanada K, Yang L, Ishitsuka K, et al. Allergic profiles 
of mothers and fathers in the Japan Environment and Children's 
Study (JECS): a nationwide birth cohort study. World Allergy Organ 
J. 2017;10(1):24.
 28. Melen E, Bergstrom A, Kull I, et al. Male sex is strongly associated 
with IgE- sensitization to airborne but not food allergens: results up 
to age 24 years from the BAMSE birth cohort. Clin Transl Allergy. 
2020;10:15. https://doi.org/10.1186/s1360 1- 020- 00319 - w
 29. Warm K, Lindberg A, Lundbäck B, Rönmark E. Increase in sensitization 
to common airborne allergens among adults - two population- based 
studies 15 years apart. Allergy Asthma Clin Immunol. 2013;9(1):20.
 30. Meulenbroek LA, Knippels LM. Cord blood IgE: fetal or maternal? 
Clin Exp Allergy. 2015;45(6):1012- 1014.
 31. Nambu M, Shintaku N, Ohta S. Relationship between cord blood 
level of IgE specific for Dermatophagoides pteronyssinus and aller-
gic manifestations in infancy. Biol Neonate. 2003;83(2):102- 106.
 32. Oldak E. Cord blood IgE levels as a predictive value of the atopic 
disease in early infancy a review article. Rocz Akad Med Bialymst. 
1997;42(1):13- 17.
 33. Bonnelykke K, Pipper CB, Bisgaard H. Sensitization does not de-
velop in utero. J Allergy Clin Immunol. 2008;121(3):646- 651.
 34. Du Toit G, Roberts G, Sayre PH, et al. Identifying infants at high 
risk of peanut allergy: the Learning Early About Peanut Allergy 
(LEAP) screening study. J Allergy Clin Immunol. 2013;131(1):135- 
143.e131- 112.
 35. Ierodiakonou D, Garcia- Larsen V, Logan A, et al. Timing of aller-
genic food introduction to the infant diet and risk of allergic or au-
toimmune disease: a systematic review and meta- analysis. JAMA 
2016;316(11):1181- 1192.
 36. Prescott SL, Smith P, Tang M, et al. The importance of early com-
plementary feeding in the development of oral tolerance: concerns 
and controversies. Pediatr Allergy Immunol. 2008;19(5):375- 380.
 37. Ferraro V, Zanconato S, Carraro S. Timing of Food Introduction and 
the Risk of Food Allergy. Nutrients. 2019;11(5):1131.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Tedner SG, Söderhäll C, Konradsen 
JR, et al. Extract and molecular- based early infant 
sensitization and associated factors— A PreventADALL study. 
Allergy. 2021;00:1–10. https://doi.org/10.1111/all.14805
